News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 621
- Sources here
- 21
- Companies here
- 15
Search results
Stored financial headlines
Active search
621 matching headlines
Ticker or company: SUMMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Summit Hotel Properties (INN) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Senior Vice President, Corporate Finance - Kevin MilotaPresident and Chief Executive Officer - Jon StannerExecutive Vice President, Corporate Development - Adam Wudel TAKEAWAYS Pro Forma RevPAR Growth -- …
INN
main company
Sharemaestro market context
Trend signal active
52 weeks +17.1%
Reynolds Consumer Products Inc. (REYN) Stock Forecasts
Argus has lowered its target price for Reynolds Consumer Products Inc. (REYN) to $27.00. The company, a provider of household products including cooking, waste, storage, and tableware, is currently trading at $26.23. The report suggests further reading requires a Yahoo Finance Silver subscription.
REYN
main company
Sharemaestro market context
Trend signal active
52 weeks +15.6%
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $28.34, Implies 88% Upside
Summit Therapeutics Inc.'s average 12-month price target has been lowered to $28.34 from $29.52 by 14 analysts, yet this new target still suggests an 88% upside from its Aug. 11 closing price. The consensus rating for the stock remains a "Buy" among 18 analysts.
SMMT
main company
Sharemaestro market context
Price below Trend Line
52 weeks -49.0%
Summit Therapeutics (SMMT) Stock Gains on China Label Expansion for Ivonescimab
Summit Therapeutics (SMMT) shares rose after China's National Medical Products Administration approved a label expansion for its bispecific antibody ivonescimab, allowing its first-line use with chemotherapy for advanced squamous non-small cell lung cancer. Despite an extremely high price-to-sales ratio and ongoing losses, insider purchases …
SMMT
main company
Sharemaestro market context
Price below Trend Line
52 weeks -49.0%
Sumitomo Mitsui Financial Group Inc Stock (SMFG) Moved Up by 3.82% on Aug 12: A Full Analysis
Sumitomo Mitsui Financial Group (SMFG) stock rose by 3.82% due to market expectations of the Bank of Japan's monetary policy normalization and strong first-quarter earnings. Higher interest rates are expected to boost net interest income, and disciplined capital management coupled with positive analyst sentiment …
Sharemaestro market context Trend signal active 52 weeks +74.7% · Next-week setup positive 59.3%Summit higher as partner Akeso wins China label expansion for lead drug
[Approved red stamp sign.] * Shares of Summit Therapeutics (SMMT [https://seekingalpha.com/symbol/SMMT]) traded higher on Wednesday after the Chinese drug regulator, the National Medical Products Administration, approved a label expansion for the company’s lead drug, ivonescimab, developed with Akeso (AKESF [https://seekingalpha.com/symbol/AKESF]). * According to Summit …
Sharemaestro market context Price below Trend Line 52 weeks -31.8% · Next-week setup negative 7.4%Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC
Summit Therapeutics announced that its partner Akeso has received approval in China for ivonescimab for use in squamous non-small cell lung cancer (NSCLC). This approval marks a significant milestone for the bispecific antibody, which combines immunotherapy and anti-angiogenesis effects. Ivonescimab is also being developed …
SMMT
main company
Sharemaestro market context
Price below Trend Line
52 weeks -49.0%
Summit Therapeutics (NASDAQ:SMMT) Upgraded at Leerink Partners
Leerink Partners upgraded Summit Therapeutics (NASDAQ:SMMT) from "underperform" to "market perform" with a $13 price target. The company currently holds an average "Hold" rating from analysts with an average price target of $24.25, and recently reported quarterly EPS of -$0.28, missing estimates. Insider buying …
SMMT
main company
Sharemaestro market context
Price below Trend Line
52 weeks -49.0%
3 Reasons REYN is Risky and 1 Stock to Buy Instead
3 Reasons REYN is Risky and 1 Stock to Buy Instead Reynolds trades at $26.52 and has moved in lockstep with the market. Its shares have returned 14.9% over the last six months while the S&P 500 has gained 11%. Is now the time …
REYN
main company
Sharemaestro market context
Trend signal active
52 weeks +15.6%
Dimensional Fund Advisors LP Sells 200,688 Shares of Summit Hotel Properties, Inc. $INN
Dimensional Fund Advisors LP reduced its stake in Summit Hotel Properties (NYSE:INN) by 13.3% in the first quarter, selling 200,688 shares but still holding 1.31 million shares valued at $5.77 million. The REIT reported stronger-than-expected Q1 earnings of $0.04 EPS and revenue of $199.02 …
INN
main company
Sharemaestro market context
Trend signal active
52 weeks +17.1%
Consumer portfolio services’ Sr. VP Ralston sells $13,138 in stock
Catrina Marie Ralston, Senior Vice President at CONSUMER PORTFOLIO SERVICES, INC. (NASDAQ:CPSS), sold a total of $13,138 worth of company stock across two transactions in August 2026. Following these sales, Ms. Ralston directly holds 71,879 shares. The company recently reported a significant increase in …
CPSS
main company
Sharemaestro market context
Trend signal active
52 weeks +12.3%
UBS Group AG Reduces Stake in Summit Hotel Properties Inc (INN) by 32%
UBS Group AG has reduced its stake in Summit Hotel Properties Inc (INN) by 31.97%, selling over 4.1 million shares. Despite this significant reduction, INN represents only 0.01% of UBS's total portfolio. Summit Hotel Properties is a REIT focusing on upscale select-service hotels, currently …
INN
main company
Sharemaestro market context
Trend signal active
52 weeks +17.1%
Summit Midstream (SMC) Stock Jumps On Profit Turn As Cash Flow Draws Focus
Summit Midstream (SMC) stock rose 8.9% after reporting a shift from a loss to a small profit in Q2 2026, driven by strong operating cash flow. The company's adjusted earnings per share reached US$0.33, and adjusted EBITDA hit US$60.7 million, indicating a positive turn …
SMC
main company
Sharemaestro market context
Trend signal active
52 weeks +69.1%
Earnings call transcript: Summit Midstream beats Q2 2026 estimates, lifts outlook
Summit Midstream Corp. reported stronger-than-expected Q2 2026 results, with adjusted earnings and revenue surpassing analyst estimates due to increased volumes in the Rockies and Mid-Con segments. The company raised its full-year adjusted EBITDA guidance to $235 million-$255 million and saw its shares climb in …
SMC
main company
Sharemaestro market context
Trend signal active
52 weeks +69.1%